Nov 4
ADPT · Adaptive Biotechnologies Corp
$29.04
-0.44 (-1.49%)
At close · Nov 13
Return incl. dividend (before tax)
Market Cap
$4.70B
Shares
161.88M
Volume · Nov 13
2.06M
Avg daily vol (3M)
2.18M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$29.04
Open$29.69
Day$28.39–29.78
52W close$12.41–30.26
Avg vol 30d2.2M
Short int11.5M · 7.1% of shares · 6.1d
Short vol52%
Last earningsNov 4, 2026
DataJan 2020–Nov 2026
Filing10-Q · Nov 4
Up next
Feb 4, 2027
Est · unconfirmed
· in 12 wks
Latest documents
2026
Nov 4
Quarterly report
10-Q
FY2026 Q3, ended Sep 30
Revenue rises despite wider net loss
Adaptive Biotechnologies Corporation recognized $226.3 million of revenue for the nine months ended September 30, 2026, while net loss attributable to the company was $56.9 million. Cash, cash equivalents and marketable securities totaled $400.2 million.
Revenue $83.9M
▼ 10.7%
Net income $2.88M
▼ 69.9%
Diluted EPS $0.02
▼ 66.7%
Nov 4
Current report
8-K
Reports profitability, raises MRD revenue outlook
Adaptive Biotechnologies achieved total company profitability in the third quarter of 2026, with revenue of $83.9 million, net income of $2.8 million and adjusted EBITDA of $14.3 million; it raised full-year MRD revenue guidance to $276 million to $286 million.
Aug 4
Quarterly report
10-Q
FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2
AI summary on its way
Revenue $71.55M
▲ 21.5%
Net loss $39.79M
Diluted EPS -$0.25
Jul 29
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$298.01M
Trailing 12 months
Net income (TTM)
−$70.52M
Trailing 12 months
Revenue growth YoY
-10.7%
Year over year
Operating margin
-16.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$75.61M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.5%
Year over year · more shares
Price change (1Y)
+105.4%
Trailing year
Short interest
7.1%
Latest settlement · 6.1 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26
TL;DR. Adaptive raised full-year MRD revenue guidance, achieved total-company profitability with $14.3 million of adjusted EBITDA and $7.7 million of free cash flow, and delivered 44% core MRD revenue growth. Risks include an 11% year-over-year decline in reported revenue, a year-over-year decline in GAAP net income to $2.8 million, pressure on realized ASP, erroneous data submitted on the Clonosec PLA, no near-term positive EPS outlook, and a 70% year-over-year decline in Immune Medicine revenue.
Bullish
- + Q3 achieved total-company profitability with $14.3 million of adjusted EBITDA and $7.7 million of free cash flow.
- + Full-year MRD revenue guidance was raised to $276 million-$286 million from $268 million-$278 million.
- + Core MRD revenue excluding milestones grew 44% year over year.
- + Sequencing gross margin expanded to 73% from 66% year over year.
- + Pharma backlog increased 34% year over year to approximately $270 million.
- + Updated guidelines and a new definition of cure strengthened Clonosec's clinical foundation in multiple myeloma.
Bearish
- − Reported Q3 revenue declined 11% year over year to $83.9 million.
- − Management does not expect positive EPS for Q4 or the full year.
- − Medicare testing beyond the four-test bundle is pressuring realized ASP.
- − Erroneous data was submitted on the Clonosec PLA, and the company says CMS should not rely on it to set a price point.
- − Immune Medicine revenue declined 70% year over year to $11.3 million.
- − GAAP net income declined year over year to $2.8 million from $9.5 million.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 19.3 · elevated
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+45%
above
Price vs 50-day avg
+8%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
93%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+21%
trailing
6-month return
+106%
trailing
YTD return
+79%
this year
Relative strength
+105%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $20 — 50d above 200d
Institutional flow
Accumulating
267 of 305 funds reported for Sep 30 · net +3.8M sh shares · +43 new
Insider flow
Distributing
Net -$19.0M over 90 days · 100% sells
Short interest
Falling
7.09% of shares out · ▼ -4.3% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
305 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
+55%
Y/Y
EPS growth
+64%
Y/Y
Free cash flow
$-48.9M
Balance sheet
$60.7M
net debt
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jul 29, 2026
full-year
MRD revenue
Raised
$268M – $278M
May 5, 2026
$260M – $270M
changed to
Jul 29, 2026
$268M – $278M
Full-year operating expense guidance
$350M – $355M
this year
Clinical testing volume growth
38% – 40%
2026
Average selling price per test
$1,400
Sequencing gross margin
at least 70%
Previous outlook
earlier release
· from the Earnings Call filed May 5, 2026
Still-open targets the latest release did not restate under the same label.
MRD clinical volumes growth
· full year 2026
at least 35%
Total operating expense, including cost of revenue
· full year 2026
$350M – $360M
Immune Medicine cash burn
· full year 2026
$15M – $20M
Guided vs delivered
· last 3 settled
Revenue
full year 2023
guided $205M – $215M
$170.28M
Miss −18.9%
Revenue
full year 2022
guided $185M – $190M
$185.31M
In line
Revenue
full year 2021
guided $148M – $155M
$154.34M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+45%
Bullish
Price vs 50-day avg
+8%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
93%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $27 › 200d $20 — 50d above 200d
Institutional flow
Accumulating
267 of 305 funds reported for Sep 30 · net +3.8M sh shares · +43 new
Insider flow
Distributing
Net -$19.0M over 90 days · 100% sells
Short interest
Falling
7.09% of shares out · ▼ -4.3% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
305 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $12
Now $29 · 93%
Range high $30
vs 200-day avg +45%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| clonoSEQ test volume | 36,111 | the three months ended June 30, 2026 filing | — |
| Immune Medicine Adjusted EBITDA non-GAAP | -6.27M | Three Months Ended June 30, 2026 filing | — |
| MRD Adjusted EBITDA non-GAAP | 9.12M | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADPT
this stock
Adaptive Biotechnologies Corp
|
$4.70B | +78.8% | +54.8% | — | 7.1% |
|
TMO
Thermo Fisher Scientific Inc.
|
$259.44B | +20.8% | +14.5% | 36.9 | 1.3% |
|
DHR
Danaher Corp
|
$163.94B | +1.8% | +8.5% | 38.1 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.48B | +4.1% | +10.4% | 47.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.04B | +27.8% | +6.4% | 34.2 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
SEC Filings
Latest
10-Q
- Filed
- Nov 4, 2026
- This year
- 16
Adaptive Biotechnologies Corporation recognized $226.3 million of revenue for the nine months ended September 30, 2026, while net loss attributable to the company was $56.9 million. Cash, cash equivalents and marketable securities totaled $400.2 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADPT | +3.8% | +20.9% | +105.5% | +9.0% | +78.8% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +1.2% | +22.1% | +105.0% | +9.2% | +68.2% |
Key facts
CIK
1478320
CUSIP
00650F109
13F (30d)
257 filings
230 filers
Visit website
Investor relations